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Abstract
Porphyromonas gingivalis triggers a range of innate immune responses in the host that may contribute to the development of 
periodontitis and dementing diseases including Alzheimer’s disease (AD). This study aimed to assess the mode of action of 
trans-resveratrol in modulating the P. gingivalis lipopolysaccharide (PgLPS) induced metabolic inflammation in a neuronal 
cell model. Confluent IMR-32 neuroblastoma cells were treated with trans-resveratrol from Polygonum cuspidatum in the 
presence or absence of PgLPS. The abundance of messenger ribo-nucleic acid (mRNA) transcripts of a panel of 92 genes 
was quantitatively assessed through targeted transcriptome profiling technique and the biochemical pathways affected were 
identified through Ingenuity Pathway Analysis. Gene expression analysis revealed that trans-resveratrol down-regulated the 
mRNA of multiple gene markers including growth factors, transcription factors, kinases, trans-membrane receptors, cytokines 
and enzymes that were otherwise activated by PgLPS treatment of IMR-32 neuroblastoma cells. Pathway analysis demon-
strated that the cellular oxidative stress caused by the activation of phosphoinositide-3-kinase/Akt1 (PI3K/Akt1) pathway 
that leads to the production of reactive oxygen species (ROS), chronic inflammatory response induced by the activation 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway and nutrient utilization pathways were 
favourably modulated by trans-resveratrol in the PgLPS challenged IMR-32 cells. This study demonstrates the potential 
of trans-resveratrol as a bioactive compound with multiple modes of intracellular action further supporting its therapeutic 
application in neuroinflammatory diseases.
Keywords Metabolic inflammation · Neuron · NF-kB · Oxidative stress · Reactive oxygen species · LPS · Biochemical 
pathways
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease 
characterized by the presence of insoluble amyloid-beta 
(Aβ) deposits called plaques and intraneuronal neurofibril-
lary tangles together with clinical signs of a deteriorating 
memory. AD has an inflammatory component that often 
follows the development of the AD hallmark lesions. The 
microbial infections (bacteria/viruses) are implicated in the 
pathophysiology of AD and their relevance is the subject 
of current intensive research. We have reported the asso-
ciations of Porphyromonas gingivalis lipopolysaccharide 
(PgLPS) in the brains of AD patients [1] and others have 
recently confirmed the presence of this bacterium in the 
brains of AD patients [2]. Further proof of concept studies 
in which, P. gingivalis was inoculated into the mouths of 
apolipoprotein E knock-out  (APOE−/−) mice demonstrated 
P. gingivalis bacterial DNA and LPS had entered the brains 
of  APOE−/− mice [3], where the infection caused a signifi-
cant increase in oxidative stress [4].
To understand the precise role of P. gingivalis in the 
development of hallmark lesions of AD, numerous stud-
ies performed oral infections with P. gingivalis or injected 
its lipopolysaccharide (LPS) in mice have supported the 
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mechanism of inflammation that deteriorates further with 
aging [5, 6]. Studies investigating either P. gingivalis or 
its outer membrane protein, PgLPS in vitro and in vivo 
[2, 3, 5, 7–9] suggest that this bacterium and its virulence 
factors play an important role in the pathophysiology of 
both periodontitis and AD. PgLPS is a potent immuno-
genic molecule that can alter immune homeostasis through 
altering the levels of the amyloid precursor protein, the 
parent protein of the Aβ plaque lesion in AD. AD is a 
disease in which advancing age is a major risk factor and 
consequently, has the underlying inflammatory component 
deeply rooted in the innate immune system and metabolic 
inflammation. Hence, the precise role of the interplay of 
the innate immune and metabolic responses need to be 
better understood.
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a bio-
active polyphenol naturally produced in plants such as 
grapes, berries, peanuts, tea and the root of Polygonum 
cuspidatum [10]. Trans-resveratrol has been reported to 
have numerous health benefits including anti-inflamma-
tory, anti-diabetic, anti-oxidant and neuroprotective, and 
has been traditionally used in oriental medicine [11, 12]. 
Growing evidence suggests that resveratrol has antimicro-
bial properties against a range of bacterial species, viruses 
and fungi [13]. Resveratrol inhibits the expression of vir-
ulence factor and interferes in biofilm formation where 
P. gingivalis is a keystone pathogen [14]. Resveratrol is 
a lipophilic polyphenol that can easily pass through the 
blood–brain barrier and hence is of particular interest for 
its bioactivity in neuronal health [15]. The neuroprotective 
role of trans-resveratrol against cellular oxidative damage 
has been previously reported [16]. In addition, several res-
veratrol derivatives have also been tested for their poten-
tial benefits in preventing neuronal cell death due to Aβ 
deposition (an antimicrobial peptide in AD brains) taking 
place in the brain [17].
P. gingivalis can contribute to systemic and intracerebral 
pools of Aβ as well [8, 9]. It is therefore plausible to suggest 
that P. gingivalis oral infection due to severe periodontitis 
has metabolic implications to an individual’s peripheral and 
brain health. Neurons in the brain are vulnerable to oxida-
tive stressors and a report by Kim et al. [18] suggested that 
resveratrol has a neuroprotective role by directly blocking 
the cellular oxidative stress caused by the release of reactive 
oxygen species (ROS). Resveratrol, despite being a highly 
bioactive molecule with a range of protective effects in the 
chronic inflammatory diseases, its therapeutic use in neuro-
inflammatory diseases particularly in the context of PgLPS 
induced oxidative stress and innate immune response are yet 
to be fully explored. This study aimed to assess the mode 
of action of trans-resveratrol in modulating the P. gingivalis 
LPS induced metabolic inflammation in the neuroblastoma 
IMR-32 in vitro cell model.
Materials and methods
Cell culture
The human neuroblastoma IMR-32 (ATCC) cell line was 
maintained in T25 flasks in Dulbecco’s modified Eagle’s 
medium (DMEM, Lonza UK) supplemented with 10% 
foetal bovine serum (FBS) Sigma-Aldrich, UK), 5 mM 
Pen/strep, 5 mM L glutamine, 5 mM sodium pyruvate 
(all from Gibco UK). The cell culture media was replaced 
every other day and incubated at 37 °C in a humidified 
atmosphere of 5%  CO2, 95% air until they reached about 
90% confluence. The confluent cells were detached using 
1 mL of (1x) trypsin (Gibco UK)/flask and pelleted by 
centrifugation. The cell density was determined using a 
Countess® cell counting chamber slides (ThermoFisher, 
Scientific, UK).
IMR-32 cells are relatively slow-growing cells with a 
population doubling time of approximately 48 h. Fully 
confluent (> 90%) cells were used for PgLPS treatment 
in this study. For the treatment, the cells were seeded at 
2 × 104 cells/mL in a six-well plate. The cells reached a 
state of > 90% confluence within 6–7 days of seeding. On 
the day prior to treatment, the media was replaced with 
1 mL serum and antibiotic-free media and cells were kept 
in the incubator for overnight. Then, cells were treated 
with 25  μM of 98% trans-resveratrol (Kingherbs Ltd. 
Hunan, China) from P. cuspidatum in the presence/absence 
of 10 µg/mL commercial PgLPS from P. gingivalis (tlrl-
ppglps, InvivoGen, France). The concentration of trans-
resveratrol (25 μM) was chosen based on the fact that 
resveratrol had no adverse effect on the cell viability and 
cytotoxicity up to 50 μM [19, 20]. The PgLPS dose was 
selected based on the fact that a concentration of 10 µg/
ml PgLPS was reported to effectively induced intracellu-
lar oxidative and inflammatory cascades in murine mac-
rophages [21]. The DMEM media without PgLPS served 
as a carrier control. Following 24 h incubation in the 
presence of PgLPS and resveratrol, the supernatants were 
removed and the cells were harvested in 1 ml Trizol solu-
tion and stored at − 20 °C until used for RNA extraction.
RNA extraction
Total RNA was extracted from the cells using GenElute 
Total RNA Miniprep Kit (Sigma-Aldrich Corp.) accord-
ing to the manufacturer’s instructions. Total RNA was 
subjected to DNAse I (Sigma-Aldrich Corp.) treatment to 
eliminate genomic DNA contamination. Column purifica-
tion of the RNA was performed using GenElute mamma-
lian total RNA miniprep kit (Sigma-Aldrich Corp.). Total 
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RNA was finally suspended in 50 μl 0.1% diethylpyrocar-
bonate (DEPC) treated water and stored at − 80 °C. The 
quality and quantity of the total RNA were assessed in a 
NanoDrop-ND1000 Spectrophotometer (Thermo Fisher 
Scientific Inc. MA, USA). The cDNA synthesis was per-
formed with 1 μg of total RNA using the RevertAid H 
minus first-strand cDNA synthesis kit (Fermentas GmbH, 
St. Leon-Rot, Germany) following the manufacturer’s pro-
tocol. The final volume of cDNA was adjusted to 150 μl 
with nuclease-free water.
Quantitative real‑time PCR (qPCR)
The expressions of a panel of 92 genes were evaluated using 
a qPCR array, performed in a QuantStudio 5 real-time PCR 
system (Applied Biosystems). This is a custom-designed 
96-well array that included 92 target genes and four inter-
nal controls. The 92 target genes included representing the 
common markers of the inflammatory immune cascade. 
This panel of genes was previously reported to capture the 
intracellular signalling pathways associated with the chronic 
inflammation induced by LPS treatment [22]. Single internal 
control and 3 reference genes were also included on each 
plate. For this PCR array experiment, 25 μl cDNA (after 
1:5 dilution) from each replicate within a single treatment 
group was pooled. QPCR was performed on a 20 μl reaction 
mixture per well containing 1 μl pooled cDNA, 9 μl water 
and 10 μl SYBR green master mix (Applied Biosystems). 
The thermal cycling conditions were 94 °C for 30 s fol-
lowed by 60 °C for 1 min, for 40 cycles. In this experiment, 
a CT value of 35 was considered as the cut-off limit. The 
relative quantities  (2–ΔCt) of the target genes were normal-
ized using the geometric mean of the relative quantities of 
three internal control genes (beta-actin (ACTB), hypoxan-
thine–guanine phosphoribosyl transferase 1 (HPRT1) and 
beta-2 microglobulin (B2M). Briefly, average ΔCt was 
calculated as the difference of Ct values of any target gene 
minus the geometric average of the Ct value of the three ref-
erence genes. Then, fold change was calculated as  2(− average 
ΔCt target gene)/2(− average ΔCt reference gene).
Pathway Analysis
The fold change values (cut off ± 1.5 fold) were analyzed 
using Qiagen Ingenuity Pathway Analysis and the relevant 
canonical pathways were identified using the default setting 
in the software. The statistical probability (P value) of the 
observed number of genes affecting a particular biologi-
cal function was calculated based on Fisher’s Exact Test. 
This P  value indicated the statistical probability of the 
observed number of genes affected out of the total number of 
genes evaluated in the PCR array for the biological function. 
The correlation between the relationship direction and gene 
expression was determined by calculating the Z-score fol-
lowing the formula Z = (N+ − N−)/√ N where,  N+ represents 
the number of genes whose expression follows the same 
direction while  N− represents the number of genes whose 
expression follows an opposite direction of the expression 
of a particular gene compared to that already available in 
the IPA knowledge database. N indicates the total number of 
genes affected. A high stringency Z-score between ≥  + 2.0 
or ≤  − 2.0 were applied to identify the most relevant signal-
ling pathways.
Statistical analysis
This experiment involved technical replicates on three inde-
pendent occasions and an equal volume of cDNA was pooled 
from each of the three replicates representing the treatment 
group, the relative mRNA abundance values for each pool 
was considered as the mean for the treatment group.
Results
Differential expression of genes by trans‑resveratrol
Of the 92 target genes evaluated, compared to the car-
rier control the PgLPS treatment resulted in the rela-
tive abundance of mRNA transcripts increased for 49 
genes, decreased for 7 genes and no alteration in 36 genes 
(Fig. 1a). Among the key genes up-regulated by > twofold 
(Table 1) were transcription factors (FOXO1, STAT1, STAT3, 
CREB1, EGR2, IRF1, FOS, RELA, NFKB1), kinases (AKT1, 
PIK3R1, GSK3B, PCK1, CSF1R, IRAK1, JAK2, MAPK3K1, 
IKBKB, INSR), receptors and associated protein (VCAM1, 
MYD88, CD40, TNFRSF1A, IGF1R, PTGER1, HRH3), 
enzymes (PTGS2, IRS1, TRAF2, ADA, FTO, HADH) and 
cytokines (TNFA, IL1B, CSF1, CSF2, IL6, IL8 and IL17A). 
The 7 genes down-regulated by PgLPS were GSTP1, SOD1, 
SOD2, TGFB1, RETN, ADIPOQ and LEPR.
Trans-resveratrol, in the presence of PgLPS challenge 
increased the mRNA transcript abundance of 19 genes, 
decreased of 44 genes with no alteration of 29 genes 
(Fig. 1b). Among the key 19 genes that were up-regulated 
by trans-resveratrol by a magnitude of > twofold (Table 1) 
include ADIPOQ, IRS1, GSTP1, SOD1, SOD2, CSF1R, 
CD40, RETN, IGF1, EGR2, EGF, PCK1, IL17A, NOD2, 
CSF2, DPP4, MUC5AC, TGFB1 and LEPR. The 44 genes 
down-regulated by trans-resveratrol include transcription 
factors (CREB1, FOXO1, FOS, IRF1, JUN, NFKB1, RELA, 
STAT1, STAT3 and SREBEF1), kinases (AKT1, PIK3R1, 
GSK3B, IKBKB, INSR, IRAK1, IRAK2, JAK2 and MAP3K1), 
receptors (IGF1R, MYD88, IL6R, HRH3, TNFRSF1A, 
PTGER1 and VCAM1), enzymes (ADA, FTO, HADH, IDE, 
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PLAT, PTGS2, and TRAF2) and cytokines (TNFA, IL6, IL1B 
and CSF1).
The biochemical pathways altered 
by trans‑resveratrol in IMR‑32 cells
Based on the expression of genes differentially expressed by 
the trans-resveratrol treatment in PgLPS challenged IMR-
32 cells, the intracellular signalling pathways were identi-
fied (Table 2). Trans-resveratrol significantly (P < 0.001; 
z-score cut off < − 2.000) inhibited pathways of cellular 
oxidative stress including the production of NO and ROS 
as indicated by the lower mRNA abundance of AKT1, FOS, 
IKBKB, IRF1, JAK2, MAPK3K1, NFKB1, PIK3R1, RELA, 
STAT1, TNFA and TNFRSF1 genes and iNOS signaling as 
indicated by a decrease in the mRNA abundance of FOS, 
IKBKB, IRAK1, IRAK2, IRF1, JAK2, NFKB1, RELA and 
STAT1 genes. Trans-resveratrol also inhibited the major 
inflammatory signalling pathways such as NF-kB signal-
ling (18 genes), neuro-inflammatory signalling (22 genes), 
acute phase response (18 genes), IL-6 pathways (15 genes), 
IL-8 pathways (12 genes) and CD40 pathways (10 genes). 
For the nutrient metabolic pathways, trans-resveratrol acti-
vated PTEN pathways (9 genes), PPARa/RXRa pathways 
(10 genes) and PPAR signalling pathways (10 genes) while 
inhibited IGF-1 pathways (9 genes) and insulin receptor 
pathways (8 genes).
Discussion
Resveratrol is a bioactive polyphenol that has numerous 
health benefits including immuno-modulatory properties. 
The LPS of P. gingivalis (PgLPS), an anaerobic pathogen, 
implicated in periodontal disease induces innate immune 
responses that have far-reaching consequences in the 
immune and metabolic health of the host. In this study, the 
transcript abundance of a panel of key biomarkers altered 
by trans-resveratrol in the presence of PgLPS in IMR-32 
neuroblastoma cells was evaluated. Gene expression analysis 
revealed that the markers of cellular oxidative stress, inflam-
matory pathways and glucose homeostasis as induced by 
the PgLPS treatment were altered by trans-resveratrol. This 
study demonstrates the potential of trans-resveratrol as a bio-
active compound that has multiple modes of action including 
therapeutic potential in some neuroinflammatory diseases.
P. gingivalis and its LPS are predominantly found in the 
oral cavity, potentially contributing to dementing diseases of 
late-onset [1, 2, 7]. In Alzheimer’s patients, the circulating 
plasma level of LPS was reported to be 61 ± 42 pg/ml versus 
21 ± 6 pg/ml in the healthy volunteers [23]. In cell culture 
experiment, even a concentration of 10 ng/ml PgLPS caused 
only a mild response, however, a higher concentration of 
PgLPS (10 µg/ml) effectively induced intracellular oxida-
tive and inflammatory cascades in murine macrophages [21]. 
Hence, PgLPS 10 µg/ml was used to treat the cells in this 
experiment. In this study, PgLPS treatment of IMR-32 cells 
resulted in a conspicuous up-regulation of key signalling 
molecules including transcription factors, kinases, mem-
brane receptors, growth factors, enzymes and cytokines. 
Taken together, this data indicates the plausible activation 
of the oxidative and inflammatory cascades.
An LPS mediated activation of pro-inflammatory 
response is expected to occur through the involvement of 
pathogen recognition receptors (PRRs) molecules such as 
the toll-like receptors 4 (TLR-4) and 2 (TLR-2) and via 
MyD88 route leading to the activation of NF-kB [24]. 
This was evident from the increase mRNA abundance of 
MyD88, a number of genes of NF-kB pathway as well 
as major downstream inflammatory cytokines including 
TNFa, IL6 and IL1B indicating that PgLPS indeed induced 
the inflammatory signal cascade in IMR-32 cells. In peri-
odontal inflammation, PgLPS was reportedly increased the 
levels of major inflammatory cytokines including TNFa, 
Fig. 1  Relative abundance of 
mRNA transcripts of genes in 
the IMR-32 neuroblastoma cells 
subjected to Porphyromonus 
gingivalis lipopolysaccharide 
(PgLPS) treatment only (1a) 
or PgLPS and trans-resveratrol 
(1b)
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Table 1  Differential expression of genes caused by Porphyromonus gingivalis lipopolysaccharide (PgLPS) treatment only or PgLPS and trans-
resveratrol in the IMR-32 neuroblastoma cells (fold change values ≥ 2.0 and ≤  − 2.0 folds are shown)
Genes Location Type of molecules PgLPS PgLPS + trans-
resveratrol
MYD88 innate immune signal transduction adaptor (MYD88) Plasma membrane Adapter protein  + 4.87 − 2.96
Tumor necrosis factor alpha (TNFA) Extracellular space Cytokine  + 4.39 − 2.32
Interleukin 1 beta (IL1B) Extracellular space Cytokine  + 4.61 − 3.06
Colony stimulating factor 1 (CSF1) Extracellular space Cytokine  + 5.34 − 29.33
Interleukin 6 (IL6) Extracellular space Cytokine  + 67.17 − 11.30
Interleukin 8 (IL8) Extracellular space Cytokine  + 22.51 –
Colony stimulating factor 2 (CSF2) Extracellular space Cytokine  + 3.10  + 10.96
Interleukin 17A (IL17A) Extracellular space Cytokine  + 2.60  + 9.82
Prostaglandin-endoperoxide synthase 2 (PTGS2) Cytoplasm Enzyme  + 2.49 − 2.71
Insulin receptor substrate 1 (IRS1) Cytoplasm Enzyme  + 5.77  + 4.78
Glutathione S-transferase pi 1 (GSTP1) Cytoplasm Enzyme − 3.13  + 5.51
TNF receptor associated factor 2 (TRAF2) Cytoplasm Enzyme  + 4.16 − 12.25
Adenosine deaminase (ADA) Cytoplasm Enzyme  + 4.71 − 39.38
FTO alpha-ketogluterate dependent dioxygenase (FTO) Nucleus Enzyme  + 4.26 − 15.16
Superoxide dismutase 1 (SOD1) Cytoplasm Enzyme − 3.98  + 3.06
Superoxide dismutase 2 (SOD2) Cytoplasm Enzyme − 3.21  + 5.60
Hydroxyacetyle Co-A dehydrogenase (HADH) Cytoplasm Enzyme  + 4.44 − 23.79
Prostaglandin E receptor 1 (PTGER1) Plasma membrane G-protein coupled receptor  + 2.72 − 12.62
Histamine receptor H3 (HRH3) Plasma membrane G-protein coupled receptor  + 6.25 − 119.21
Epidermal growth factor (EGF) Extracellular space Growth factor –  + 9.31
Insulin like growth factor 1 (IGF1) Extracellular space Growth factor –  + 8.78
Transforming growth factor beta 1 (TGFB1) Extracellular space Growth factor − 4.84  + 36.00
Vascular endothelial growth factor A (VEGFA) Extracellular space Growth factor – − 13.35
Phosphoenol pyruvate carboxylase 1 (PCK1) Cytoplasm Kinase  + 2.38  + 9.67
Colony stimulating factor 1 receptor (CSF1R) Plasma membrane Kinase  + 3.44  + 5.70
Interleukin 1 receptor associated kinase 1 (IRAK1) Plasma membrane Kinase  + 3.26 − 68.45
Glycogen synthase kinase 3 beta (GSK3B) Nucleus Kinase  + 4.40 − 2.70
Janus kinase 2 (JAK2) Cytoplasm Kinase  + 3.59 − 61.71
Phoshpoinositide-3 kinase regulatory subunit 1 (PIK3R1) Cytoplasm Kinase  + 6.08 − 5.28
Mitogen activated protein kinase kinase kinase 1 (MAP3K1) Cytoplasm Kinase  + 5.16 − 6.10
Inhibitor of nuclear factor kappa B kinase subunit beta 
(IKBKB)
Cytoplasm Kinase  + 3.14 − 10.25
Interleukin 1 receptor associated kinase 2 (IRAK2) Plasma membrane Kinase – − 17.32
AKT serine/threonine kinase 1 (AKT1) Cytoplasm Kinase  + 3.78 − 78.92
Insulin receptor (INSR) Plasma membrane Kinase  + 4.38 − 47.27
Nuclear receptor subfamily 4 group A member 2(NR4A2) Nucleus Ligan-dependent nuclear receptor  + 2.63 − 2.96
Dipeptidyl peptidase 4 (DPP4) Plasma membrane Peptidase –  + 12.00
Mucin 5AC, oligomeric mucus/gel-forming (MUC5AC) Cytoplasm Peptidase –  + 22.46
Plasminogen activator, tissue type (PLAT) Extracellular space Peptidase  + 2.87 − 5.81
Insulin degrading enzyme (IDE) Extracellular space Peptidase  + 7.03 − 41.87
Glucose-6 phosphatase catalytic subunit (G6PC) Cytoplasm Phosphatase  + 20.16 − 2.03
Early growth response 2 (EGR2) Nucleus Transcription regulator  + 3.31  + 9.20
Interferon regulatory factor 1 (IRF1) Nucleus Transcription regulator  + 2.32 − 151.71
Signal transducer and activator of transcription 1 (STAT1) Nucleus Transcription regulator  + 4.08 − 14.09
cAMP responsive element binding protein 1(CREB1) Nucleus Transcription regulator  + 6.13 − 18.41
Fos proto-oncogene, AP-1 transcription factor subunit (FOS) Nucleus Transcription regulator  + 12.90 − 24.27
Forkhead box O1 (FOXO1) Nucleus Transcription regulator  + 7.22 − 42.19
RELA proto-oncogene, NF-kB subunit (RELA) Nucleus Transcription regulator  + 2.22 − 44.64
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Table 1  (continued)
Genes Location Type of molecules PgLPS PgLPS + trans-
resveratrol
Nuclear factor kappa B subunit 1 (NFKB1) Nucleus Transcription regulator  + 4.27 − 48.93
Signal transducer and activator of transcription 3 (STAT3) Nucleus Transcription regulator  + 2.81 − 88.34
Sterol regulatory element binding transcription factor 1 
(SREBEF1)
Nucleus Transcription regulator  + 4.23 − 174.32
Jun proto-oncogene, AP1 transcription factor subunit (JUN) Nucleus Transcription regulator – − 3.12
Interleukin 6 receptor (IL6R) Plasma membrane Trans-membrane receptor  + 9.91 − 2.62
Leptin receptor (LEPR) Plasma membrane Trans-membrane receptor − 2.17  + 42.48
CD40 molecule (CD40) Plasma membrane Trans-membrane receptor  + 4.53  + 7.12
Vascular cell adhesion molecule 1 (VCAM1) Plasma membrane Trans-membrane receptor  + 3.89 − 3.57
TNF receptor superfamily member 1A (TNFRSF1A) Plasma membrane Trans-membrane receptor  + 2.88 − 19.77
Insulin like growth factor 1 receptor (IGF1R) Plasma membrane Trans-membrane receptor  + 5.89 − 64.43
Uncoupling protein 2 (UCP2) Cytoplasm Transporter  + 6.51 − 20.67
TNF receptor associated factor 5 (TRAF5) Cytoplasm Transporter  + 3.91 − 33.05
Low density lipoprotein receptor (LDLR) Plasma membrane Transporter  + 3.19 − 85.47
Nucleotide binding oligomerization domain containing 2 
(NOD2)
Cytoplasm – –  + 10.84
Resistin (RETN) Extracellular space – − 6.15  + 8.10
Adiponectin, C1Q and collagen domain containing (ADI-
POQ)
Extracellular space – − 4.14  + 6.66
GRB2 associated binding protein 1 (GAB1) Cytoplasm –  + 7.40 − 18.91
Table 2  Canonical pathways and the gene affected by the trans-resveratrol in presence of Porphyromonus gingivalis lipopolysaccharide (PgLPS) 
treatment in the IMR-32 neuroblastoma cells
Pathways Effect Genes affected within the pathway Z-score P-value
Oxidative stress
Production of NO and ROS Inhibition AKT1, FOS, IKBKB, IRF1, JAK2, MAP3K1, NFKB1, PIK3R1, RELA, STAT1, 
TNF, TNFRSF1
− 2.309 1.51E−13
iNOS signaling Inhibition FOS, IKBKB, IRAK1, IRAK2, IRF1, JAK2, NFKB1, RELA, STAT1 − 2.330 6.10E−17
Inflammation
NF-kB signaling Inhibition AKT1, CD40, EGF, GSK3B, IGF1R, IKBKB, IL1B, INSR, IRAK1, MAP3K1, 
MYD88, NFKB1, PIK3R1, RELA, TNFA, TNFRSF1A, TRAF2, TRAF5
− 2.089 2.02E−27
Neuroinflammation signaling Inhibition AKT1, CD40, CREB1, CSF1R, FOS, GSK3B, IDE, IKBKB, IL6, IL1B, IL6R, 
IRAK1, IRAK2, JAK2, MYD88, NFKB1, PIK3R1, PTGS2, RELA, SOD2, 
STAT1, TGFB1
− 2.000 2.70E−32
Acute phase response Inhibition AKT1, FOS, IKBKB, IL6, IL1B, IL6R, IRAK1, JAK2, MAP3K1, MYD88, NFKB1, 
PIK3R1, RELA, SOD2, STAT3, TNF, TNFRSF1A, TRAF2
− 2.186 9.55E−24
IL-6 signaling Inhibition AKT1, FOS, IKBKB, IL6, IL1B, IL6R, JAK2, NFKB1, PIK3R1, RELA, STAT3, 
TNF, TNFRSF1A, TRAF2, VEGFA
− 2.324 3.89E−21
IL-8 signaling Inhibition AKT1, EGF, FOS, IKBKB, IRAK1, IRAK2, NFKB1, PIK3R1, PTGS2, RELA, 
VCAM1, VEGFA
− 2.111 2.75E−13
CD40 signaling Inhibition CD40, FOS, IKBKB, NFKB1, PIK3R1, PTGS2, RELA, STAT3, TRAF2, TRAF5 − 2.333 1.61E−15
Metabolism
PTEN signaling Activation AKT1, FOXO1, GSK3B, IGF1R, IKBKB, INSR, NFKB1, PIK3R1, RELA 2.121 6.43E−11
PPARa/RXRa activation Activation ADIPOQ, IKBKB, IL6, IL1B, INSR, IRS1, JAK2, NFKB1, RELA, TGFB1 2.111 4.61E−12
PPAR signaling Activation FOS, IKBKB, IL1B, INSR, NFKB1, PTGS2, RELA, TNF, TNFRSF1A, TRAF2 2.001 4.26E−15
IGF-1 signaling Inhibition AKT1, FOS, FOXO1, IGF1, IGF1R, IRS1, JAK2, PIK3R1, STAT3 − 2.121 2.63E−13
Insulin receptor signaling Inhibition AKT1, FOXO1, GAB1, GSK3B, INSR, IRS1, JAK2, PIK3R1 − 2.017 1.97E−10
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IL-6, IL-1B and IL-17 [25, 26]. These pro-inflammatory 
cytokines can potentially contribute to the development of a 
systemic chronic inflammatory condition and pathophysiol-
ogy of other inflammatory diseases such as cardiovascular 
diseases and type-2 diabetes [3, 5]. Thus, an unhygienic oral 
environment with generalised periodontitis may negatively 
affect a number of human inflammatory, but chronic diseases 
because of the common signalling cascades being activated. 
The drive to combat chronic diseases, which lower the indi-
vidual’s quality of life, is to improve lifestyle habits [27, 28].
In this study, the anti-oxidative and anti-inflammatory 
effects of trans-resveratrol were evident from the down-
regulation of a number of key regulatory kinases, trans-
membrane receptors, enzymes and inflammatory cytokines 
all together indicating a potential therapeutic application 
of resveratrol in P. gingivalis mediated pro-inflamma-
tory disease that may eventually lead to AD. Resveratrol 
(3,5,4′-trihydroxy-trans-stilbene), a polyphenol naturally 
present in many plant components and long known for its 
anti-oxidative, anti-inflammatory properties and its role in 
glucose metabolism, has been used in the oriental medi-
cine for centuries [29]. We identified that the anti-oxidative 
activity of trans-resveratrol is mediated through inhibition 
of two vital oxidative stress pathways (production of nitric 
oxide (NOS) and reactive oxygen species (ROS) and iNOS 
signalling pathways. ROS are oxygen-containing molecules 
produced as a result of cellular metabolism and are required 
for facilitating the transfer of electrons in the redox reactions 
as well as serving as a second messenger [30]. Uncontrolled 
oxidative stress is associated with metabolic inflammation 
as well as neurodegenerative diseases such as AD [31, 32]. 
In AD, ROS interacting with Aβ leads to the production and 
accumulation of toxic compounds and plaque formation ulti-
mately leading to synaptic loss and a compromised cognitive 
function in AD pathogenesis [30, 32]. Another mechanism 
of ROS in AD pathogenesis involves its contribution towards 
the progressive loss of neuronal autophagy, a vital mecha-
nism through which cell degrades the cytoplasmic proteins 
and organelles [30, 33].
Underlying bioactivity of trans-resveratrol could be medi-
ated via the inhibition of phosphor-inositol 3 kinase (PI3K)/
AKT1 pathway because the mRNA abundance of PI3KR1, 
a regulatory PI3K, along with AKT1, a serine/threonine 
kinase were inhibited by trans-resveratrol in the presence 
of PgLPS. The PI3K/AKT1 pathway plays an important 
role in the cellular oxidation process and contributes to the 
pathophysiology of neurodegenerative diseases [34]. While 
the PI3K/AKT pathway is indispensable for maintaining the 
homeostatic level of cell growth, survival and differentia-
tion and metabolism of nutrients [34], during the cellular 
oxidative stress PI3K together with AKT1, trigger the pro-
duction of ROS [35, 36]. AKT1 is involved in the phos-
phorylation of a number of signalling molecules such as 
glycogen synthase kinases 3 beta (GSK-3B), forkhead box 
class O1 (FOXO1) and NF-kB [34]. Along with PI3KR1 
and AKT1, the mRNA abundance of these markers was also 
down-regulated by trans-resveratrol in this experiment. An 
LPS-mediated inflammatory response mediated through its 
receptor molecule TLR4 is also associated with the activa-
tion of AKT1 [37]. However, in this experiment, no change 
in the TLR4 mRNA was evident while cells were treated 
with trans-resveratrol in the presence of PgLPS. A poten-
tially underlying cause could be that because the cells were 
harvested 24 h post-treatment, a time scale regarded suf-
ficient to dampen the TLR4 expression caused by a higher 
level of AKT1 expression over time [38].
The bioactivities of trans-resveratrol are known to 
affect the oxidative stress pathways, systemic inflamma-
tory signalling and glucose metabolic pathways [39, 40]. 
Such broad-spectrum bioactivities of trans-resveratrol was 
exhibited by affecting the GSK-3B, an important regulatory 
molecule involved in the phosphorylation of a number of 
proteins and transcription factors involved in these three 
interconnected pathways [34, 40]. In addition to the PgLPS 
mediated inflammatory process, GSK-3B also contributes 
to excessive phosphorylation of the microtubule binding 
protein tau which eventually caused their collapse leading 
to neurofibrillary tangle formation, which is the second diag-
nostic hallmark of AD neuropathology [30, 41]. Another 
mechanism through which GSK-3B promotes the inflam-
matory process is through phosphorylation of STAT3, an 
important transcription factor required for the induction of 
pro-inflammatory cytokines that translocate into the nucleus 
following phosphorylation and activation [41]. Transcrip-
tion factor CREB1 involved in the TLR mediated inflam-
mation serves as a substrate for GSK-3B [40]. The impor-
tance of GSK-3B molecule in LPS mediated inflammatory 
response was demonstrated by the fact that inhibition of 
GSK-3B effectively saved mice from the deleterious effect 
of a lethal doze of LPS [42]. In this experiment together 
with GSK3B, the mRNA abundance of STAT3 and CREB1 
were also down-regulated indicating the therapeutic appli-
cation of trans-resveratrol in PgLPS mediated deleterious 
pro-inflammatory response.
GSK-3B also plays a major role in the nutrient metabo-
lism through directly interacting with insulin and mTOR 
molecules and directing the nutrient energy towards the 
anabolic path leading to cell growth [40]. Expression of 
GSK-3B is vital for homeostasis as the complete elimination 
of GSK-3B is fatal for cell survival as demonstrated in the 
knockdown embryonic model [42]. In contrast, a temporary 
inhibition was found to increase in glucose uptake as well 
as a higher expression of GLUT1 [43]. GSK-3B also func-
tions as a negative regulator of mitochondrial energy pro-
duction that is mediated through controlling the AMPK, a 
cellular energy-sensing molecule, and inhibition of pyruvate 
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dehydrogenase activity [44]. In this experiment, while the 
mRNA levels of G6P, an entry point of glucose into the 
energy metabolism and mitochondrial uncoupling protein 
2 (UCP2) were inhibited by trans-resveratrol; two other 
markers of glucose metabolism (IRS1 and PCK1) remained 
unaffected. This potentially complex mechanism of trans-
resveratrol action in nutrient metabolism via affecting GSK-
3B warrants further investigation.
FOXO1 belongs to the FoxO, forkhead box class O 
(FoxO) cluster of transcription factors that phosphoryl-
ates and acetylates proteins at serine, threonine and lysine 
residues and is involved in the oxidative stress and insulin 
action [34, 45]. Both insulin resistance and oxidative stress 
can enhance the transcriptional activity of FOXO1 that can 
again contribute to the development of hyperglycemia and 
the production of ROS [46]. FOXO1 can also activate c-Jun 
N-terminal kinase and inhibit Wingless (Wnt) pathways and 
can contribute to β-amyloid plaque formation and phospho-
rylation of s protein potentially leading to neurodegenera-
tion [46]. In response to the P gingivalis infection that often 
results in a compromised barrier function of the mucosal/
gingival epithelium, the PgLPS is expected to increase the 
FOXO1 expression [45]. Then, a subsequent translocation of 
FOXO1 into the nucleus is expected to cause transcriptional 
activation of a number of inflammatory mediators bearing 
a FOXO1 promoter responsive element [45]. FOXO1 acti-
vates a number of downstream molecules involved in the 
wound healing process of the epithelial barrier [47]. In this 
experiment, in addition to a reduction in the mRNA abun-
dance of FOXO1, trans-resveratrol also down-regulated the 
abundance of few interesting downstream molecules such as 
pro-inflammatory cytokines (IL1B, TNFA), wound healing 
factor (VEGF) and adhesion molecule (VCAM1). TGFB is 
another FOXO1 target molecule that plays a vital role in the 
wound healing process [45]. Trans-resveratrol increased the 
mRNA abundance of TGFB suggesting its beneficial role in 
the PgLPS induced inflammatory damage.
Another interesting molecule with multiple protective 
functions in cell survival and metabolism is the phosphatase 
and tensin homolog (PTEN), a tumor suppressor that antago-
nizes phosphatidylinositol 3-kinase type I (PI3K) and thus 
affecting PI3K/AKT pathways [48]. PTEN is a tumour sup-
pressor molecule that catalyses converting of PIP3 to PIP2 
and reverses the PI3K/AKT activities. PTEN can increase 
energy expenditure in brown adipose tissue and enhance 
longevity at organism level indicating that an increase in 
PTEN activity could be beneficial [49]. One of the bioactiv-
ity of trans-resveratrol includes up-regulation of the PTEN 
pathway [48] that is associated with concomitant inhibition 
of PI3K/AKT functions. An outcome of this response is an 
up-regulation of genes involved in triggering the antioxi-
dant pathways such as catalases and superoxide dismutase 
enzymes [48]. Our pathway analysis identified the activation 
of PTEN pathways as a potential mechanism of underlying 
anti-oxidant bioactivities of trans-resveratrol which is also 
conspicuous in the down-regulation of the mRNA abun-
dance of major genes of PTEN pathway including AKT1, 
FOXO1, GSK3B, PIK3R1 and NF-kB associated markers. 
Besides, a potential triggering of genes involved in the anti-
oxidant mechanism such as SOD1, SOD2 and GSTP1 [50] 
was also evident in this study further demonstrating mul-
ticomponent mechanisms underlying the trans-resveratrol 
mediated bioactivity in IMR-32 cells.
In conclusion, this study of targeted transcriptome profil-
ing identified a number of biochemical signalling pathways 
affected in the IMR-32 neuroblastoma cells when treated 
with PgLPS. The gene expression analysis revealed that the 
trans-resveratrol has multiple highly effective bioactivities 
that work through modulating the interconnected mecha-
nisms of cellular oxidative stress, inflammatory response 
and nutrient metabolism. Hence, the therapeutic application 
of trans-resveratrol in P. gingivalis mediated disease patho-
physiology may be explored. Based on the altered expression 
of multiple markers of cellular oxidative stress, inflamma-
tory pathways and nutrient metabolism, the PgLPS treated 
IMR-32 cells may be a good in-vitro model of P. gingivalis 
induced innate immune cascade that could eventually lead 
to the development of AD.
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